ValiRx (LSE:VAL) ROCE % : -65.48% (As of Jun. 2024)

View and export this data going back to 2000. Start your Free Trial

What is ValiRx ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ValiRx's annualized ROCE % for the quarter that ended in Jun. 2024 was -65.48%.

ValiRx ROCE % Historical Data

The historical data trend for ValiRx's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx ROCE % Chart

ValiRx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-103.37

-43.68

-40.58

-71.00

-67.99

ValiRx Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															-69.71	-92.84	-58.90	-66.65	-65.48

ValiRx ROCE % Calculation

ValiRx's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-2.299	/	( ( (3.976 - 0.128)	+	(3.13 - 0.215) )	/ 2 )
	=	-2.299	/	( (3.848	+	2.915)	/ 2 )
	=	-2.299	/	3.3815
	=	-67.99 %

ValiRx's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-2.104	/	( ( (3.13 - 0.215)	+	(3.692 - 0.181) )	/ 2 )
	=	-2.104	/	( ( 2.915	+	3.511 )	/ 2 )
	=	-2.104	/	3.213
	=	-65.48 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

ValiRx (LSE:VAL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ValiRx ROCE % Related Terms

Thank you for viewing the detailed overview of ValiRx's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

EAJF:Germany

Address

D6 Thane Road, MediCity Nottingham, Nottingham, GBR, NG90 6BH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.